Acute myeloid leukemia (AML) cells of subtypes M4 and M5 show enhanced expression of CD64 (Fc;RI), the highaffinity receptor for IgG, which is normally expressed at high levels only on activated cells of the myeloid lineage. CD64 is therefore a prime target for the specific delivery of cytotoxic agents. A promising toxin candidate is granzyme B, a human serine protease originating from cytotoxic granules of CD8 + T lymphocytes and natural killer cells. After evaluating the sensitivity of the AML-related cell line U937 toward cytosolic granzyme B, we genetically fused granzyme B to H22, a humanized single-chain antibody fragment (scFv) specific for CD64, to obtain Gb-H22(scFv), a fusion protein lacking the immunogenic properties of nonhuman immunofusions. Gb-H22(scFv) was successfully expressed in human 293T cells, secreted, and purified from cell culture supernatants. The purified protein bound specifically to CD64 + U937 cells. Despite linkage to the binding domain, the proteolytic activity of functional Gb-H22(scFv) was identical to that of free granzyme B. Target cell-specific cytotoxicity was observed with a half-maximal inhibitory concentration (IC 50 ) between 1.7 and 17 nmol/L. In addition, the induction of apoptosis in U937 cells was confirmed by Annexin A5 staining and the detection of activated caspase-3 in the cytosol. Finally, apoptosis was observed in primary CD64 + AML cells, whereas CD64 À AML cells were unaffected. This is the first report of a completely human granzyme B-based immunotoxin directed against CD64, with activity against an AML-related cell line and primary AML cells. [Mol Cancer Ther 2008;7(9):2924 -32] 
Introduction
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and is estimated to have affected 13,410 people and accounts for 8,990 deaths in 2007 in the United States (1) . It is a heterogeneous group of malignancies having in common the overproliferation of hematopoietic stem cells and their failure to differentiate, leading to uncontrolled accumulation of myeloblasts in bone marrow and blood (2) . Current treatment strategies for AML generally comprise two phases. First, induction chemotherapy eradicates all hematopoietic precursor cells from the bone marrow, allowing repopulation of the blood with normal cells. After remission, a second therapeutic phase is applied to remove residual cells that are likely to account for a relapse. Current approved postremission therapeutic strategies include intensive consolidation chemotherapy, high-dose chemotherapy with or without radiation therapy, low-dose maintenance therapy, and autologous or allogenic hematopoietic stem cell transplantation (3, 4) . For both induction and postremission therapy, the risks and benefits of the therapeutic approach have to be evaluated and stratified according to the patient's age and general condition, disease progression, cytogenetic aberrations of leukemic cells, and expression of proteins that confer multidrug resistance or that are pivotal to the regulation of cell proliferation and survival (3, 4) .
In contrast to the therapies described above, which are directed at hematopoietic cells in general and thus can cause severe side effects, the specific targeting and elimination of malignant cells only is to be preferred. This can be achieved using immunoconjugates based on antibodies or natural ligands that are directed to cellspecific surface receptors. Indeed, AML cells have been successfully targeted via the receptors for interleukin-3 (5) and granulocyte-macrophage colony-stimulating factor (6, 7) as well as via CD33 (8) . One of these immunoconjugates is gemtuzumab ozogamicin (Mylotarg), an anti-CD33 antibody chemically coupled to the organic bacterial drug calicheamicin, which was approved by the Food and Drug Administration in 2000 (8) . However, severe hematologic and hepatotoxic side effects caused at least in part by insufficient targeting have limited its therapeutic application (9, 10) . Similar issues have been reported for DT388-GM-CSF (11) . We therefore decided to target AML cells via another cell surface receptor, CD64, whose expression is enhanced on AML subtypes M4 and M5 but not restricted to these subtypes (12) .
The 72-kDa glycoprotein CD64 (FcgRI) is the only IgG receptor that binds monomeric IgG with high affinity (13) . It is expressed on cells of the myeloid lineage (monocytes, macrophages, and dendritic cells). These cells can be activated by several cytokines that up-regulate CD64, including IFN-g, which plays a crucial role in inflammatory responses and causes a 5-to 10-fold increase of CD64 expression as well as enhanced receptor activity (14) . CD64 mediates endocytosis/phagocytosis, antibody-dependent cellular cytotoxicity, and production of cytokines and superoxide (15) . It also influences the severity of various inflammatory diseases such as rheumatoid arthritis (16) , allergic asthma (17) , and atopic dermatitis (18) .
Previous studies focusing on the targeting of dysregulated CD64
+ cells in cutaneous inflammation and arthritis have shown that anti-CD64 immunotoxin treatment successfully eliminated CD64 + activated macrophages but left resting macrophages with low CD64 expression unaffected (19, 20) . The key element here is not the degree of CD64 expression but rather the actual state of activation of these cells. Therefore, CD64 might also be an effective target in the therapy of AML. Indeed, anti-CD64 immunofusions with Ricin A as well as with Pseudomonas exotoxin A (ETA ¶) proved to be potent triggers of apoptosis in CD64 + AML cells (21, 22) . However, protein domains of nonhuman origin can provoke undesirable immune responses. To avoid this, we decided to use human granzyme B as the toxic moiety.
The serine protease granzyme B is an essential component of the granules released by cytotoxic T cells and natural killer cells (23, 24) . The cosecreted protein perforin delivers granzyme B to the cytosol of target cells (25) , where its proteolytic activity induces apoptosis. Known substrates of granzyme B include several caspase zymogens, among which procaspase-3 was described to be processed as the first and most important substrate (26) . Granzyme B also cleaves several caspase substrates as well as caspase-independent proteins such as Bid, providing multiple routes to initiate apoptosis (26) . For granzyme B activity, a free NH 2 terminus was described as crucial (27) .
To study the cytotoxicity of an anti-CD64-granzyme B immunoconjugate, we chose the AML-related lymphoma cell line U937, a model cell line of the myeloid lineage that can be activated with IFN-g resulting in enhanced CD64 expression. After first evaluating the sensitivity of U937 cells toward human granzyme B by expressing the enzyme in the cytosol (28), we genetically fused human granzyme B to H22, a humanized CD64-specific scFv that has been used in previous studies (29, 30 ). An enterokinase cleavage site directly preceding granzyme B allows the NH 2 terminus of the enzyme to be exposed. Here, we describe the successful expression of EGb-H22(scFv) in human 293T cells, its purification, its activation by enterokinase cleavage to obtain Gb-H22(scFv) featuring a free NH 2 terminus of granzyme B, and its functional characterization in terms of binding, proteolytic, and cytotoxic properties.
Materials and Methods

Construction of Plasmids
Escherichia coli strain XL1-Blue (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F ¶ proAB lacI q ZDM15 Tn10 (Tet r )]) (Stratagene) was used for all cloning procedures. Primers were supplied by MWG Biotech. Restriction and ligation enzymes were delivered by New England Biolabs. Plasmids or plasmid fragments were prepared and purified using the QIAprep Spin Miniprep Kit and QIAquick Gel Extraction Kit (Qiagen). Cloning was done according to standard techniques (31) .
The sequence encoding mature granzyme B was amplified from human blood-derived RNA and cloned into a pMS vector (32, 33) to obtain pMS-LKGb-II, a plasmid encoding Ki4(scFv)-granzyme B, as described elsewhere (32) .
To obtain a plasmid encoding active granzyme B for cytosolic expression, the sequence of mature granzyme B was amplified from pMS-LKGb-II (32) using t h e p r i m e r s G b f o r ( 5 ¶-a t t a c a g c t a g c c a c c a t g -ATCATCGGGGGACATGAGG-3 ¶) and Gb+BlpI+EcoRIrev ( 5 ¶-a t t a c a g a a t t c t c a g t g c t c a g c G T A G C G T T T C -ATGGTTTTCTTTATC-3 ¶), introducing restriction sites for NheI, BlpI, and EcoRI (granzyme B sequences in uppercase, additional sequences in lowercase, restriction sites in bold). The PCR product was inserted into the backbone of pMS-LKGb-II via NheI and EcoRI to yield pMS-Gb (Fig. 1A) . A control pMS vector encoding H22(scFv) was constructed in a similar manner using pMT-H22-ETA ¶ as the template (21) The pMS vector encoding the Gb-H22(scFv) fusion protein was constructed by amplifying granzyme B from pMS-LKGb-II (32) with primers adding an enterokinase cleavage site (shown in italic) to the NH 2 terminus of granzyme B [XbaI-Entero-Gb (5 ¶-gctctagacatatcgacgacgacgacaag ATCATCGGGGGACATGAGG-3 ¶) and His6 (5 ¶-ttaaactcaATGATGATGATGATGATG-3 ¶)]. The PCR product was inserted into the backbone of pMS-NAngK-III/G (33) using XbaI and BlpI. The Ign leader sequence (isolated from pMS-LKGb-II) was inserted following NheI/ XbaI digestion. The resulting plasmid pMS-LEGbK-IV was digested with SfiI/NotI to remove the binding domain Ki4(scFv) and replace it with H22(scFv), which was obtained from pMT-H22-ETA ¶ (21). The final plasmid was named pMS-LEGbH22-IV ( Fig. 2A) .
Cell Lines and Primary Cells Primary cells from a CD64 + AML patient [f80% blasts, AML subtype M5 developed secondarily from a myelodysplatic syndrome, cytogenetic aberrations: add(7)(q36)] and a CD64
À AML patient [f80% blasts, AML subtype M1, cytogenetic aberrations: t(1;3)(p36;q21)] were obtained before treatment and after informed consent and with the approval of the Clinical Research Ethics Board of the University of Aachen. Mononuclear cells were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) and cultured with RPMI complex medium.
For activation, U937 cells as well as CD64 + AML cells (and for control purposes also CD64 À AML cells) were stimulated 1 day before use with 500 units/mL IFN-g (Sigma). U937 cells were passaged to a cell density of 1 Â 10 5 /mL before stimulation. All cells were cultured at 37jC in a 100% humidified 5% CO 2 atmosphere. Nucleofection U937 cells were transfected using the Cell Line Nucleofector Kit V (Amaxa) according to the manufacturer's instructions. Briefly, cells were centrifuged at 90 Â g for 10 min and resuspended in Cell Line Nucleofector Solution V to a final concentration of 1 Â 10 6 per 100 AL. Then, 100 AL cell suspension was combined with 1 Ag plasmid DNA, transferred to the cuvette, and nucleofected using the program V-01. After nucleofection, cells were seeded out in 12-well plates containing prewarmed RPMI complex medium. Following incubation at 37jC, 100% humidity, and 5% CO 2 , cells were analyzed by propidium iodide (PI) staining (c = 5 Ag/mL) and flow cytometry.
Expression, Purification, and Activation of Gb-H22(scFv)
293T cells were transfected using 1 Ag plasmid DNA and 3 AL Roti-Fect (Roth), which were added to 300 AL serumfree RPMI 1640 plus GlutaMAX-I (Life Technologies/ Invitrogen) and incubated for 20 min at room temperature before the transfection mixture was added to the cells. After 1 h incubation at 37jC, 100% humidity, and 5% CO 2 , 1 mL RPMI complex medium was added followed by incubation for 2 to 3 days before supernatants were checked for expression of the target protein. Subcloning was carried out in RPMI complex medium containing 100 Ag/mL zeocin (Invitrogen). Further cultivation was carried out either in RPMI complex medium or in serum-free HL-1 medium (BioWhittaker/Cambrex/Lonza) supplemented 1:100 with GlutaMAX (Invitrogen). Both media contained 100 Ag/mL zeocin for selection purposes.
Gb-H22(scFv) was enriched from cell culture supernatants by IMAC/FPLC. After centrifugation, cleared supernatants were blended with 4Â incubation buffer (pH 7.4) as described previously (33), filter sterilized, and applied to an XK16 column (Amersham/GE Healthcare) containing 5 mL Talon Superflow resin (Clontech/Takara) pre-equilibrated with 1Â incubation buffer (pH 7.4). Washing and elution were also done with the buffers described by Stocker et al. (33) modified to pH 7.4. Eluted protein was rebuffered in PBS containing 20 mmol/L Tris using a HiPrep 26/10 desalting column (Amersham/ GE Healthcare) and concentrated by centrifugation at 3,800 Â g with a Vivaspin 6 ultrafiltration spin column 5 kDa MWCO (Sartorius). Activation of the protein was achieved by overnight incubation with recombinant enterokinase (Novagen/Merck) according to the manufacturer's instructions. Protein extracted from serum-containing supernatants was further purified via cation exchange chromatography using a HiTrap SP HP 1 ml column (Amersham/GE Healthcare). Washing was carried out with PBS containing 300 mmol/L NaCl, and the protein was eluted in PBS containing 500 mmol/L NaCl. Desalting and concentration were repeated as above and the protein was filter sterilized and stored in aliquots at -80jC. The protein concentration was determined with Roti-Nanoquant (Roth). Purity was calculated after SDS-PAGE analysis and Coomassie staining using AIDA Image Analyzer Software (Raytest Isotopenmessgeräte).
SDS-PAGE and Western Blot Protein samples were analyzed by SDS-PAGE using a 12% SDS gel and reducing conditions followed by Coomassie staining or Western blotting according to standard techniques (31) . The protein was detected with rabbit polyclonal anti-enterokinase cleavage site antibody (Novus Biologicals) and goat anti-rabbit IgG Fc alkaline phosphatase conjugate (Dianova). Blots were developed using NBT/BCIP [3.33% (w/v) NBT, 1.67% (w/v) BCIP in dimethylformamide], all supplied by Roth, added to the 100Â volume of alkaline phosphatase buffer [100 mmol/L Tris, 100 mmol/L NaCl, 5 mmol/L MgCl 2 (pH 9.6)]. Cell Viability Assays The cytotoxic effect of Gb-H22(scFv) was monitored by bioreduction of MTS to a colored formazan product by reduction equivalents generated by dehydrogenase enzymes of metabolically active cells. The quantity of formazan product as measured by absorbance at 490 nm is directly proportional to the number of living cells. 1:5 dilutions of Gb-H22(scFv) samples in RPMI complex medium were pipetted into a 96-well plate in triplicates. Wells containing zeocin (Invitrogen; final concentration 2 mg/mL) or PBS were used as positive and negative controls, respectively; 5,000 cells were seeded out to each well. Following an incubation period of 72 h at 37jC, 100% humidity, and 5% CO 2 , 20 AL Cell Titer AQ ueous One Solution (Promega) was added per well. Measurement was carried out after 4 h at 
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Activation of Endogenous Procaspase-3
The generation of active caspase-3 by cleavage of the procaspase-3 zymogen by granzyme B was monitored using Human Active Caspase-3 CBA (BD Biosciences). Briefly, 5 Â 10 5 cells in 1 mL RPMI complex medium were incubated with 150 nmol/L Gb-H22(scFv) for 24 h at 37jC, 100% humidity, and 5% CO 2 . After two washes with PBS, the cells were incubated on ice in 250 AL lysis buffer for 30 min while vortexing every 10 min. Cellular debris was pelleted by centrifugation. Clear cell lysate (50 AL) was added to 50 AL human caspase-3 capture beads and 50 AL human active caspase-3 PE detection reagent and incubated for 4 h at room temperature in the dark. After another washing step, the bead pellet was resuspended in 300 AL wash buffer and analyzed by flow cytometry. 
Apoptosis Assays Apoptosis in target cells was documented by Annexin
Results
Pretesting of the CD64 + Cell Line U937 to Determine Sensitivity to Granzyme B-Induced Apoptosis
To determine whether granzyme B could induce apoptosis in U937 cells, we constructed a eukaryotic plasmid designed for cytosolic granzyme B expression (Fig. 1A) . Following nucleofection of U937 cells and an incubation period of 24 h, PI staining and fluorescence-activated cell sorting analysis revealed 69% mortality in granzyme Btransfected cells, whereas negative control cells transfected without DNA showed only 19% mortality (Fig. 1B) . Control plasmids encoding H22(scFv) or GFP (pMAXGFP; Amaxa) each caused 28% mortality (data not shown).
Construction and Expression of Gb-H22(scFv)
Having shown that granzyme B could kill U937 cells, we genetically fused granzyme B to H22(scFv) and introduced an enterokinase cleavage site preceding the granzyme B NH 2 terminus using the eukaryotic pMS vector system (ref. 33 ; Fig. 2A) . To obtain correct post-translational modification, EGb-H22(scFv) was expressed in human 293T cells and successfully secreted in both serumcontaining and serum-free medium. DNA transfer and ongoing expression was confirmed by monitoring the green fluorescence resulting from the coexpression of cytosolic EGFP via a bicistronic mRNA (Fig. 2B) . Purification from cell culture supernatants was carried out solely by Co 2+ -based IMAC in the case of serum-free medium or using a combination of Co 2+ -based IMAC and cation exchange (squares ) and Raji cells (triangles ) were incubated with increasing concentrations of Gb-H22(scFv) for 72 h in a humidified 37jC, 5% CO 2 atmosphere. Cell viability in relation to a 100% PBS control and a 0% zeocin control was determined with a colorimetric MTS-based cell viability assay. Samples were measured in triplicate wells. Bars, SD.
chromatography in the case of serum-containing medium. In both cases, activation of granzyme B by enterokinase cleavage to obtain Gb-H22(scFv) was carried out after IMAC. SDS-PAGE analysis and Western blotting indicated the high purity of the purified protein and confirmed successful enterokinase cleavage (Fig. 2C) .
Proteolytic Activity of EGb-H22(scFv)
The synthetic granzyme B substrate Ac-IETD-pNA, which mimics the cleavage and activation site of human procaspase-3, was used to determine the proteolytic activity of enterokinase-cleaved Gb-H22(scFv) compared with the uncleaved EGb-H22(scFv). Equimolar amounts of Gb-H22(scFv) and commercially available granzyme B showed the same proteolytic activity, whereas the uncleaved EGb-H22(scFv) showed no reaction even when applied in 1,000-fold molar excess (Fig. 2D) . Therefore, Gb-H22(scFv) was chosen for the subsequent assays.
Binding Properties of Gb-H22(scFv) Binding of Gb-H22(scFv) to the human CD64 + cell line U937 confirmed the anticipated functionality of the single-chain antibody. In contrast, no binding was observed to CD64 À Raji cells, showing the specificity of the interaction (Fig. 3A) .
In vitro Cytotoxic Activity
The concentration-dependent cytotoxic effect of Gb-H22(scFv) was evaluated in a MTS-based colorimetric cell proliferation assay using CD64 + U937 and CD64 À Raji cells. After a 3-day incubation period with Gb-H22(scFv), the viability of U937 cells was dramatically reduced in a concentration-dependent manner, whereas Raji cells remained unaffected (Fig. 3B) . IC 50 values were between 1.7 and 17 nmol/L (n = 9 samples in 6 experiments). Unconjugated granzyme B showed no toxicity (data not shown).
Activation of Caspase-3
The potential of Gb-H22(scFv) to initiate the proteolytic cascade culminating in apoptosis in U937 cells was investigated via the detection of active caspase-3 in the cytosol. Cell lysates were incubated with caspase-3 capture beads. Bound caspase-3 was detected with a PE-labeled antibody specific for active caspase-3 but not procaspase-3. Significant activation of caspase-3 was observed in lysates of the cells treated with Gb-H22(scFv) compared with the untreated control (Fig. 4) , indicating that the induction of apoptosis by Gb-H22(scFv) was mediated by caspase-3.
Induction of Apoptosis in U937 Cells Apoptosis was detected in U937 cells incubated for 72 h with 150 nmol/L Gb-H22(scFv) by Annexin A5/PI staining. Whereas Raji cells remained viable during the whole incubation period, the number of viable U937 cells decreased to 3% in Gb-H22(scFv)-treated samples compared with 79% in the PBS control. Among the cells treated with Gb-H22(scFv), 18% were early apoptotic (Annexin A5+/PI-), whereas 79% were late apoptotic or dead (Annexin A5+/PI+; Fig. 5 ).
Induction of Apoptosis in Primary CD64 + AML Cells Primary CD64
+ and CD64 À AML cells were incubated for 48 h with 238 nmol/L Gb-H22(scFv). Again, apoptosis was detected via Annexin A5/PI staining. Gb-H22(scFv) induced apoptosis in CD64 + AML cells as indicated by reduction of the viable population (Annexin A5-/PI-; bottom left quadrant) combined with an increase in the populations of early apoptotic (Annexin A5+/PI-; bottom right quadrant) and late apoptotic/dead cells (Annexin A5+/PI+; top right quadrant; Fig. 6 ). Cells from a patient with CD64
À AML were left unaffected by Gb-H22(scFv).
Discussion
CD64 (FcgRI), the high-affinity receptor for IgG, is expressed in several types of AML cells even without monocytic differentiation (12, 35) . However, receptor numbers are highest in AML subtypes M4 and M5 of the older French-American-British classification, which is part of the revised classification of the WHO. A main function of CD64 is internalization, which makes it a useful target for immunotoxins. In case of the immunoconjugates targeting CD33 (8) , which is a cell adhesion molecule, or receptors such as interleukin-3 receptor (5) and granulocyte-macrophage colony-stimulating factor receptor (6, 7), which are signal transduction receptors, presumably only a small portion of the administered immunotoxin becomes internalized, whereas CD64 internalizes very efficiently (36) . Furthermore, the expression pattern of the receptor is limited, and normal, nonactivated CD64-expressing cells are not affected by immunoconjugates (19, 22, 37) . Therefore, CD64 can be considered as beneficial for the targeted delivery of cytotoxic or immunomodulating drugs.
The murine CD64-specific monoclonal antibody M22 (38) was humanized to obtain H22 (30) and converted to a single-chain format (29) . H22 and its derivatives have been used in a variety of applications including as fusion proteins with antibodies (39 -41) and toxic components such as calicheamicin (42) , Pseudomonas ETA ¶ (21) and Ricin A (19, 20, 22, 37) . Both Ricin A and ETA ¶ fusions to H22 have been used as therapeutic agents against AML cells (21, 22) . Although both fusion proteins proved to be effective, the nonhuman fusion partners could prevent repetitive administration due to the likelihood of an undesired immune response. To avoid such immunogenicity, we chose human granzyme B as the toxic component of our H22-based immunotoxin. Granzyme B is an apoptosisinducing serine protease naturally expressed and secreted by cytotoxic T lymphocytes and natural killer cells (23, 24 ).
First, we tested the sensitivity of the AML-related cell line U937 toward granzyme B by transfection with a plasmid allowing cytosolic expression of granzyme B. These experiments showed that granzyme B killed the cells efficiently, whereas control constructs and transfection procedures had no significant effect. We then genetically fused an enterokinase cleavage site to the NH 2 terminus of granzyme B and H22(scFv) to its COOH terminus and expressed the construct in human 293T cells. After IMAC enrichment, overnight incubation with or without enterokinase, and final purification by cation exchange chromatography, cleaved Gb-H22(scFv) was compared with uncleaved EGb-H22(scFv) in a proteolysis assay with a synthetic granzyme B substrate. Only the activated Gb-H22(scFv) showed the same proteolytic activity as free granzyme B, whereas the uncleaved EGb-H22(scFv) failed to cleave the synthetic substrate (Fig. 2D) . We therefore decided to focus further experiments on Gb-H22(scFv).
Gb Bid and other caspase-independent substrates; ref. 47 ). This implies that granzyme B has additional benefits as a toxic component, because the development of avoidance strategies by tumor cells is therefore much more difficult than with toxins acting by a single apoptosis-inducing mechanism.
Additionally, based on the work of Zhong et al. (22) , who worked with H22 coupled to Ricin A, we could show that Gb-H22(scFv) induced apoptosis in primary CD64 + AML cells, whereas CD64
À AML cells were unaffected. However, the susceptibility of cancer cells toward a granzyme B-based immunotoxin is likely to vary between patients and cell types. Therefore, with an aim to develop individualized therapies, the cytosolic expression approach could provide a rapid prescreening method to evaluate the sensitivity of malignant cells from particular patients toward granzyme B ex vivo.
A known bottleneck in the application of all immunotoxins is the translocation of the immunotoxin to the cytosol. In its natural function, granzyme B is secreted from cytotoxic T cells and natural killer cells along with perforin, which serves as endosomolytic agent to release granzyme B to the cytosol of target cells (48) . Nevertheless, cytosolic translocation has been achieved for granzyme B immunotoxins without coadministration of any endosomolytic agent as shown herein and in previous reports (28, 44 -46) . However, Dalken et al. (43) worked with granzyme B immunotoxins targeting EGFR and ErbB2, respectively, and showed that granzyme B-induced cell death could be achieved within 14 h if chloroquine was coadministered. We also tested chloroquine but found that cell death occurred in the presence of this reagent alone, even at concentrations fivefold lower than previously used (ref. 43 ; data not shown). Whether an increase in cytotoxic efficacy of our constructs can be accomplished with other endosomolytic agents or adapter sequences mediating translocation (49) is currently being investigated in our group. Animal studies with disseminated tumor models similar to those carried out by Barth et al. (50) will further elucidate the applicability of Gb-H22(scFv) in vivo.
In the clinic, Gb-H22(scFv) could be useful for both induction and postremission therapy. When used in combination therapy with conventional chemotherapeutics, it might be possible to reduce the dose of the chemotherapeutic or its frequency of administration, thus limiting side effects and promoting long-term remission. Furthermore, the treatment of inflammatory diseases that are characterized by enhanced CD64 expression on dysregulated macrophages (16 -18) lies within the range of possible applications.
In summary, we were able to produce recombinant Gb-H22(scFv), the first granzyme B-based human immunotoxin targeting CD64, in human 293T cells. Following purification and activation of the protein, we showed specific binding to and elimination of CD64 + U937 cells as well as patient-derived CD64 + AML cells in vitro.
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